Results 1 to 10 of about 3,302 (197)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib. [PDF]

PLoS ONE
BackgroundAlthough filgotinib, a selective Janus kinase 1 inhibitor, has been increasingly applied in the treatment of inflammatory diseases, its comprehensive safety profile remains insufficiently characterized.
Yinli Shi, Shuang Guan, Sicun Wang, Muzhi Li, Yanan Yu, Jun Liu, Weibin Yang, Zhong Wang   +7 more
doaj   +3 more sources

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis

Rheumatology and Therapy, 2023
Introduction This post hoc analysis of the phase 3 rheumatoid arthritis (RA) filgotinib clinical trial program assessed the effect of filgotinib on body mass index (BMI) in patients with RA and the impact of BMI on the efficacy and safety of filgotinib ...
Hans-Dieter Orzechowski, Alejandro Balsa, Patrick Verschueren   +2 more
exaly   +7 more sources

Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis – report of two filgotinib-treated cases and literature review [PDF]

Acta Oncologica
Background and purpose: Treatment of cancer with immune checkpoint inhibitors (ICIs) entails a risk of immune-related adverse events (irAEs). Data on the treatment of immune-related enterocolitis (irEC) in patients with inadequate symptom control after ...
Henrik Ekedahl, Gudbjörg Sigurjonsdottir, Viktoria Bergqvist, Björn Båtshake, Ana Carneiro, Jan Marsal   +5 more
doaj   +3 more sources

Immune‐Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report [PDF]

Clinical Case Reports
Moderate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease.
M. J. van derHoff, F. El‐Morabit, M. Löwenberg   +2 more
doaj   +3 more sources

Comparison of the Efficacy of Different Doses of Filgotinib in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on the RCTs [PDF]

Dose-Response
Objective This study compared the efficacy of different doses of filgotinib (100 mg vs 200 mg) in the treatment of rheumatoid arthritis (RA). Methods We conducted a systematic review of 4 electronic databases up to January 2025.
Xia Ye, Sidong Zhu, Dongying Wang, Lifeng Hu, Yudie Li, Qingping Wu, Jingqi Chen, Bangsheng Chen   +7 more
doaj   +2 more sources

Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study

RMD Open
Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.Methods Eligible patients completing the 24-week ...
Arthur Kavanaugh, Paul Emery, René Westhovens, Mark C Genovese, Kevin L Winthrop, Rieke Alten, Dick de Vries, Lorenzo Dagna, Patrick Verschueren, Maria Greenwald, Regina Cseuz, Robin Besuyen, Vikas Modgill, Ly Huong Le   +13 more
doaj   +2 more sources

Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres

Drugs in Context
Background: Filgotinib, an oral Janus kinase 1 preferential inhibitor, has been shown to be an effective treatment for ulcerative colitis (UC) in pre-registration studies.
David Young, Sohail Rahmany, Deborah Taylor, Emma Davis, Michael Colwill, Sonia Kalyanji Mehta, Roisin Campbell, Karl Hazel, Karishma Sethi-Arora, Susan Ritchie, Ashley I Heinson, Helen Moyses, Keith Bodger, Emma Johnston, Lucy Hicks, Anjan Dhar, Jimmy Limdi, Rachel Cooney, John Paul Seenan, Kamal Patel, Alissa Walsh, Fraser Cummings   +21 more
doaj   +2 more sources

Filgotinib for the treatment of rheumatoid arthritis [PDF]

Expert Opinion on Investigational Drugs, 2017
Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy. Being proteins, they are administered parenterally. The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA ...
Peter Taylor, Serafim Kiriakidis
exaly   +3 more sources

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

RMD Open
Objectives Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse ...
Zoltan Szekanecz, Yoshiya Tanaka, Laurent Peyrin-Biroulet, Stefan Schreiber, René Westhovens, Xavier Mariette, Chris Watson, C Janneke van der Woude, Hugo ten Cate, Andreas Stallmach, Christina Charles-Schoeman, Sandrine Aspeslagh, Marc Schmalzing, Margaux Faes, Sven Borchmann, Christine Rudolph, Edmund V Ekoka Omoruyi, Paul Van Hoek, Ernest HS Choy, Tomasz Masior   +19 more
doaj   +2 more sources

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease. [PDF]

J Gastroenterol Hepatol
ABSTRACT Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab ...
Ooi CJ, Ling KL, Limsrivilai J, Wei SC, Mak JWY, Kobayashi T, Dang LM, Leong RW, Lin H, Weng MT, Ong WC, Ahuja V, Aniwan S, Hokari R, Lee WJJ, Leow AH, Leung WK, Lim WC, Makharia G, Matsuoka K, Mustaffa N, Ng SC, Philip M, Pisespongsa P, Ali RAR, Ran ZH, Simadibrata M, Sollano J, Tan M, Viet HD, Wan Ibrahim NR, Wu KC, Ye BD, Hilmi I, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD).   +34 more
europepmc   +2 more sources